[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai First Maternity and Infant Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":129},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,39,68,83,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100625708","feasibility-effects-of-a-low-gi-high-fibre-diet-in-pcos-a-prospective-cohort-study-in-remote-yunnan-100625708",false,"NCT07426146","Feasibility Effects of a Low-GI, High-fibre Diet in PCOS: a Prospective Cohort Study in Remote Yunnan","Inclusion Criteria:\n\n* PCOS diagnosis will follow the Rotterdam criteria (presence of two of the following three features: oligo-\u002Fanovulation, clinical\u002Fbiochemical hyperandrogenism, and polycystic ovarian morphology, with exclusion of related disorders). Additional inclusion criteria comprise: body mass index (BMI) ≥24 kg\u002Fm² (Chinese obesity threshold), stable weight for at least 3 months prior to enrollment (±2 kg), willingness to maintain current physical activity levels throughout the study period, and residence within the designated study area for a minimum of 6 months.\n\nExclusion Criteria:\n\n* pregnancy or lactation; type 1 diabetes or type 2 diabetes; thyroid dysfunction, hyperprolactinemia, congenital adrenal hyperplasia, Cushing's syndrome, androgen-secreting tumors, or other endocrine disorders affecting metabolism; use of hormonal contraceptives, insulin sensitizers, or anti-obesity medications within the past 3 months (e.g., metformin, GLP-1 receptor agonists, systemic corticosteroids, hormonal contraceptives, anti-androgens). Severe hepatic\u002Frenal\u002Fcardiovascular disease; gastrointestinal disorders incompatible with high-fiber diets; history of bariatric surgery; current participation in other dietary intervention programs; and individuals with cognitive impairment or language communication barriers who cannot comprehend the study procedures or provide informed consent. Participants will be required to maintain their habitual physical activity levels during the intervention period and must not initiate new weight-loss medications\u002Fsupplements; any deviations will be documented as protocol violations","FEMALE","19 Years","40 Years",{"count":19,"type":20},56,"ESTIMATED","6 Months","OBSERVATIONAL","This study aims to observe the effects of a 6-month, culturally-adapted low glycemic index-high fiber (LGI-HF) dietary on IR, androgen levels, and menstrual regularity among women with PCOS in remote areas of Yunnan Province. We hypothesize that a nutritional strategy designed for high-carbohydrate dietary habits while balancing feasibility and adherence can significantly improve patients' metabolic and reproductive parameters, thereby providing practical evidence-based guidance for long-term PCOS management in resource-limited settings",[25],"PCOS (Polycystic Ovary Syndrome)","RECRUITING","2026-02-15",{"date":29,"type":30},"2026-02-23","ACTUAL",{"date":32,"type":30},"2025-08-10",{"date":34,"type":20},"2026-04-10",{"name":36,"class":37},"Shanghai First Maternity and Infant Hospital","OTHER",2,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":15,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":49,"studyType":22,"phases":4,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100524133","a-cohort-of-maternal-vascular-malperfusion-related-fgr-comvmfgr-100524133","NCT06104748","A Cohort of Maternal Vascular Malperfusion-related FGR (CoMVMFGR)","Inclusion Criteria:\n\n1.Singleton pregnancy 2. diagnosed as FGR according the delphi consensus:\n\n1. Early-onset FGR(\\\u003C32 weeks) Estimated fetal weight (EFW) or abdominal circumference (AC) \\\u003C 3rd; or EFW or AC \\\u003C 10th, combined with abnormal doppler, including uterine artery pulsatility index(UtA PI) \\>95th percentile, umbilical artery pulsatility index(UA PI) \\>95th percentile； or umbilical artery absent end-diastolic flow (UA-AEDF) or umbilical artery reversed end-diastolic flow(UA-REDF).\n2. Late-onset FGR(≥32 weeks) Estimated fetal weight (EFW) or abdominal circumference (AC) \\\u003C 3rd; or \\>2 of the following 3 criteria:\n\n   * EFW or AC \\\u003C10th percentile\n   * EFW or AC crossing percentiles\\>2 quartiles on growth percentiles\n   * CPR \\\u003C5th percentile or UA-Pl\\>95th percentile 3.provision of signed written informed consent.\n\nExclusion Criteria:\n\n* Fetus with definitive genetic disorders related to FGR, fetus with confirmed intrauterine infection (CMV, syphilis and etc.), fetus with structural anomalies\n* Incomplete information or absence of informed consent","18 Years","45 Years",{"count":48,"type":20},500,"2 Years","Based on a precise diagnostic standard process, through a multicenter study, we will establish a cohort focusing on placenta-mediated fetal growth restriction (FGR). Long-term follow-up will be conducted to seek predictive indicators for short-term and long-term adverse outcomes of maternal vascular malperfusion-related FGR (MVM-FGR).",[52],"MVM-FGR",[54,55,56,57,58],"FGR","maternal vascular malperfusion","Doppler","placenta","etiologies","2024-06-06",{"date":61,"type":30},"2024-06-07",{"date":63,"type":30},"2023-08-10",{"date":65,"type":20},"2025-12-30",{"name":36,"class":37},1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":15,"minAge":45,"maxAge":46,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":81,"leadSponsor":82,"locationsCount":67},"100523524","prediction-of-placental-fetal-growth-restriction-in-high-risk-population-popfgr-100523524","NCT06096805","Prediction of Placental Fetal Growth Restriction in High Risk Population (PoPFGR)","Inclusion Criteria:\n\n* Pregnant women with gestational age of \\\u003C14 weeks\n* Maternal age between 18 and 45 years old\n* With at least one of FGR high risk factors:\n\n  1. Maternal age \\>40 years\n  2. Nulliparous, Maternal age \\>38 years\n  3. Previous pregnancy with FGR, PE or placental abruption\n  4. Maternal medical history of chronic hypertension, diabetes mellitus, chronic nephritis or autoimmune diseases (such as SLE or APS)\n  5. Recurrent spontaneous abortion (RSA) \\> 3 times with unknown causes\n* Or with at least two of the following FGR high risk factors:\n\n  1. Maternal age 35\\~40 years\n  2. BMI ≥ 28 kg\u002Fm2 or BMI \\\u003C 18.5 kg\u002Fm2\n  3. Conception with assisted reproductive technology\n  4. Interval from previous delivery: \\> 5 years or \\\u003C 6 months\n\n     Exclusion Criteria:\n* Presence of fetal genetic abnormalities or severe structural abnormalities in prenatal ultrasound or genetic testing.",{"count":75,"type":20},2000,"This study intends to prospectively enroll high-risk pregnant women to establish a multicenter cohort. By combining maternal basic characteristics, medical history, early pregnancy ultrasound, and biological markers, we aim to construct a joint predictive model for MVM-FGR.",[78],"Fetal Growth Retardation",{"date":61,"type":30},{"date":63,"type":30},{"date":65,"type":20},{"name":36,"class":37},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":15,"minAge":45,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":67},"100525174","shanghai-ovarian-cancer-and-family-care-project-100525174","NCT06118307","Shanghai Ovarian Cancer and Family Care Project","Participant meet the criteria for one of the following conditions:\n\n* Patients attending the oncology department require differential diagnosis of ovarian cancer.\n* Patients with known high-risk factors for ovarian cancer, such as history of ovarian cancer or BRCA-associated cancer, etc.\n* Patients attending the Physical Examination Center who have normal findings on physical examination and no symptoms.\n\nExclusion Criteria:\n\n* Individuals with evidence of another active cancer.\n* Individuals who have prior bilateral oophorectomy.\n* Individuals who are unwilling or unable to sign the informed consent form.",true,{"count":91,"type":20},3546,"Ovarian cancer is the most lethal gynaecological malignancy, but its incidence in the general population is low. Due to the lack of effective prevention and successful screening approaches, most cases are diagnosed at advanced stages, leading to poor prognosis. In order to address the research requirements pertaining to ovarian cancer, the Shanghai Ovarian Cancer and Family Care Project was established. This initiative offers hospital-based resources for investigating ovarian cancer and high-risk populations. The project comprises an on-going ovarian cancer cohort, a high-risk population cohort, and a healthy population cohort. By leveraging these comprehensive cohorts, the project provides a unique platform for in-depth studies on the detection, prevention, early diagnosis, treatment, and prognosis of ovarian cancer.",[94],"Ovarian Cancer","2023-10-31",{"date":97,"type":30},"2023-11-07",{"date":99,"type":30},"2013-01-01",{"date":101,"type":20},"2028-10-13",{"name":36,"class":37},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":15,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":114,"phases":115,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":4},"100523307","cumulative-live-birth-rates-in-dual-ovarian-stimulation-versus-two-antagonist-stimulations-in-poor-ovarian-responders-100523307","NCT06093984","Cumulative Live Birth Rates in Dual Ovarian Stimulation Versus Two Antagonist Stimulations in Poor Ovarian Responders","A Randomized Clinical Trial Comparing Cumulative Live Birth Rates in Dual Ovarian Stimulation Versus Two Antagonist Stimulations in Poor Ovarian Responders","Inclusion Criteria:\n\n* Women with POR were defined with adjusted Bologna criteria, at least two of the three following criteria: advanced maternal age (40 years); 3 oocytes in previous IVF; and antral follicle count (AFC) 5 and\u002For anti-Mu¨llerian hormone (AMH) 1.1 ng\u002Fml (this criterion was mandatory)\n* Aged from 20 to 44 years\n* Body mass index (BMI) from 19 to 32 kg\u002Fm2\n* No more than two previous IVF cycles were recruited\n\nExclusion Criteria:\n\n* Amenorrhoea\n* Follicle stimulating hormone (FSH) 20 IU\u002FL or AFC 1\n* Women with a partner with an extremely severe sperm anomaly or sperm donor use","20 Years","44 Years",{"count":113,"type":20},260,"INTERVENTIONAL",[116],"NA","To compare the difference in cumulative live birth rates between dual ovarian stimulation and two antagonist stimulations in poor ovarian responders.",[119],"Infertility","NOT_YET_RECRUITING","2023-10-17",{"date":123,"type":30},"2023-10-23",{"date":125,"type":20},"2023-11-01",{"date":127,"type":20},"2026-10-30",{"name":36,"class":37},""]